Treatment for Breast

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial will compare the rate of ipsilateral breast tumor recurrence in subjects treated with a single fraction of intra-operative radiation therapy using the Xoft Axxent Electronic Brachytherapy System to those treated with whole breast irradiation at 5 years of follow-up.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 5 years

5 years
tumor recurrence

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

50 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Medstar Health Research InstituteOTHER
172 Previous Clinical Trials
134,005 Total Patients Enrolled
MedStar Franklin Square Medical CenterLead Sponsor
1 Previous Clinical Trials
27 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The tumor(s) must be < 3.0 cm in greatest dimension by pre-operative assessment.
Subject presenting with bilateral breast cancer may be enrolled if BOTH cancers meet all of the inclusion and none of the exclusion criteria.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: November 5th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.